Acylcarnitines are molecules your body produces when it attaches fatty acids to carnitine, a small compound that acts as a shuttle for fat fuel into the energy-producing compartments of your cells. They sit at the crossroads of fat burning, and when that process runs smoothly, acylcarnitines come and go without much fanfare. When something goes wrong, though, they pile up in the blood in distinctive patterns that can signal conditions ranging from rare inherited metabolic diseases in newborns to insulin resistance, heart failure, and liver disease in adults. Their dual role as both working parts of normal metabolism and red flags for dysfunction has made them one of the more versatile biomarkers in modern medicine.
How Acylcarnitines Form
Your body runs on a mix of fuels, and fatty acids are among the most energy-dense. But long-chain fatty acids cannot cross the inner membrane of your mitochondria on their own. Carnitine solves this problem by binding to the fatty acid, creating an acylcarnitine that can be ferried across the membrane. Once inside, the fatty acid is released and chopped into smaller pieces through a process called beta-oxidation, generating the energy currency your cells need to function.
Carnitine itself comes from two places: your body synthesizes some, and you get the rest from food, especially red meat and dairy products.1PubMed Central. Carnitine transport and fatty acid oxidation A specialized transporter called OCTN2 moves carnitine into cells and helps the kidneys reclaim it before it gets flushed out in urine. The different types of acylcarnitines are named by the length of their attached fatty acid chain: short-chain (two to five carbons), medium-chain (six to twelve), and long-chain (thirteen or more). That distinction matters clinically because specific chain lengths tend to accumulate in specific diseases.
How Newborn Screening Uses Acylcarnitines
One of the highest-impact applications of acylcarnitine profiling is in newborn screening. A few drops of blood from a baby’s heel, dried on a filter paper card, can be analyzed by mass spectrometry to detect dozens of acylcarnitine species at once. Abnormal patterns point toward fatty acid oxidation disorders, organic acidemias, and other inherited metabolic conditions that, if caught early, can be managed before they cause irreversible damage.
The challenge is accuracy. Measuring individual acylcarnitines alone can produce a lot of false positives, because healthy babies sometimes have mildly elevated levels. In screening for carnitine-acylcarnitine translocase deficiency, for example, researchers found that using ratios of acylcarnitines rather than single markers dramatically cut the false-positive rate. While individual long-chain acylcarnitines could not reliably separate affected babies from false positives, ratio-based indices brought the false-positive rate down to as low as 0.02% while still catching all confirmed cases.2PubMed Central. Increased acylcarnitine ratio indices in newborn screening for carnitine-acylcarnitine translocase deficiency shows increased sensitivity and reduced false-positivity
Newer discoveries continue to refine screening. Heptadecanoylcarnitine (C17), an odd-numbered acylcarnitine that exists at very low concentrations in healthy people, has been identified as a promising marker for methylmalonic acidemia and propionic acidemia. In one screening program, C17 achieved over 91% sensitivity and nearly 100% specificity at a particular cutoff.3PubMed Central. Heptadecanoylcarnitine (C17) a novel candidate biomarker for propionic and methylmalonic acidemias during expanded newborn screening The metabolite propionylcarnitine (C3) also has established clinical relevance as a biomarker in propionic and methylmalonic acidemias.4PubMed Central. Biomarkers for drug development in propionic and methylmalonic acidemias
Genetic Disorders That Disrupt the System
When the carnitine shuttle or any of the enzymes involved in beta-oxidation is broken by a genetic mutation, the consequences can be severe. Systemic primary carnitine deficiency, caused by mutations in the SLC22A5 gene that encodes the OCTN2 transporter, prevents cells from taking up enough carnitine. Without adequate carnitine, fatty acid oxidation stalls, energy production drops, and toxic intermediates build up. The condition is inherited in an autosomal recessive pattern and needs to be distinguished from secondary carnitine deficiency, which arises from other metabolic disorders that deplete carnitine stores indirectly.5PubMed Central. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management
Another example is carnitine palmitoyltransferase 2 (CPT2) deficiency, in which the enzyme that releases fatty acids inside the mitochondria is impaired. Long-chain acylcarnitines pile up in tissues and blood. Supplementing with L-carnitine can help the body flush these abnormal intermediates. In one detailed case study of a CPT2-deficient patient, oral L-carnitine took several days to raise blood carnitine levels because the body’s intracellular stores were so depleted. A sequential pattern emerged: free carnitine peaked first, followed by acetylcarnitine, then long-chain acylcarnitines, with urinary excretion of abnormal species dramatically dropping by about two weeks, suggesting that tissue accumulation was clearing.6The Tohoku Journal of Experimental Medicine. Carnitine Palmitoyltransferase 2 Deficiency: The Time-Course of Blood and Urinary Acylcarnitine Levels during Initial L-Carnitine Supplementation
Insulin Resistance and Type 2 Diabetes
Acylcarnitine profiles are characteristically altered in people with obesity and type 2 diabetes. Blood levels of various short-, medium-, and long-chain acylcarnitines tend to be elevated, reflecting incomplete fat burning and mitochondrial stress in skeletal muscle and liver.7PubMed Central. Acylcarnitines: reflecting or inflicting insulin resistance? The idea is that when cells are overwhelmed with fatty acids, beta-oxidation cannot keep up. Partially processed fatty acid fragments get exported back into the blood as acylcarnitines, and the resulting oxidative stress in muscle tissue may itself worsen insulin resistance.8PubMed Central. Acylcarnitines: potential implications for skeletal muscle insulin resistance
There is an ongoing debate about whether acylcarnitines are merely a reflection of broken metabolism or active participants in making it worse. The evidence leans toward both being true simultaneously: they serve as markers of mitochondrial overload, and their accumulation contributes to oxidative stress that further impairs the cell’s ability to respond to insulin. This feedback loop helps explain why acylcarnitine profiles track so closely with the severity of metabolic disease.
Liver Disease and Acylcarnitine Progression
Disordered acylcarnitine metabolism also contributes to nonalcoholic fatty liver disease (NAFLD), one of the most common liver conditions worldwide.9PubMed. Theacrine protects against nonalcoholic fatty liver disease by regulating acylcarnitine metabolism A study tracking acylcarnitine species across stages of NAFLD found a telling pattern: long-chain species like AC14:1 and AC18:1 rose steadily as liver fibrosis worsened and climbed even higher in patients who had developed liver cancer. Meanwhile, a medium-chain species (AC5:0) moved in the opposite direction, dropping as fibrosis progressed.10PubMed Central. Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma This kind of divergent pattern could eventually help clinicians gauge how far liver disease has advanced using a blood test rather than a biopsy.
Heart Failure and Cardiovascular Risk
The heart is one of the most energy-hungry organs in the body, and it relies heavily on fatty acid oxidation. When the heart starts to fail, that fuel-burning machinery falters, and acylcarnitines accumulate in the bloodstream. Patients with heart failure and reduced pumping capacity showed circulating acylcarnitine levels roughly 22 to 79% higher than healthy controls, regardless of chain length, even after accounting for age, sex, kidney function, and insulin resistance.11PubMed. Circulating acylcarnitine profile in human heart failure: a surrogate of fatty acid metabolic dysregulation in mitochondria and beyond These elevations correlated with a standard severity marker for heart failure, suggesting acylcarnitines track meaningful disease progression.
The prognostic value is real. In a clinical trial analysis, long-chain acylcarnitines were grouped into a factor that predicted increased risk of death, hospitalization, and cardiovascular events. In patients with end-stage heart failure who received a mechanical heart pump, those same long-chain species dropped significantly after implantation, hinting that the metabolic dysfunction is at least partly reversible when the heart’s workload is relieved.12PubMed Central. Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support Among individual species, C16, C16:1, C18, and C18:1 showed the strongest associations with both exercise capacity and clinical outcomes in patients with diabetic heart failure, with higher levels consistently linked to worse prognosis.13PubMed Central. Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy
What Exercise Does to Your Acylcarnitine Profile
If elevated acylcarnitines signal metabolic trouble at rest, what happens during exercise, when your muscles are deliberately burning through huge amounts of fat? They go up, and that is perfectly normal. During moderate exercise at roughly 45% of peak oxygen consumption, acylcarnitine levels rose robustly and then fell again during a 20-minute cool-down period. This pattern held regardless of the person’s insulin sensitivity or fitness level, suggesting that the rise simply reflects the rate at which mitochondria are processing fatty acids to meet energy demand.14PubMed Central. Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism, and potential signals to muscle afferent neurons
This is an important nuance: context determines whether a given acylcarnitine level is healthy or worrisome. A spike during a workout is your metabolism doing exactly what it should. A persistently elevated baseline at rest, on the other hand, suggests the mitochondria are struggling to keep pace with the fatty acid supply flowing in.
Acylcarnitines in Sepsis and Critical Illness
In the intensive care unit, acylcarnitine profiles take on a different kind of significance. During sepsis, the body’s metabolic machinery goes haywire, and certain acylcarnitines spike in ways that correlate with how badly organs are failing. A multicenter study found that acetylcarnitine (the shortest acylcarnitine, with just a two-carbon chain) was uniquely informative. It correlated with levels of inflammatory cytokines, was associated with positive blood cultures for infection, and predicted 28-day mortality. Patients whose plasma acetylcarnitine reached 6,000 ng/mL or higher had dramatically higher 28-day mortality compared with those below that threshold.15PubMed. Increased Plasma Acetylcarnitine in Sepsis Is Associated With Multiple Organ Dysfunction and Mortality: A Multicenter Cohort Study This makes acetylcarnitine a potential bedside tool for gauging how aggressively to treat a critically ill patient.
Brain Health and Acetyl-L-Carnitine
Acetyl-L-carnitine (ALCAR) is the form of acylcarnitine that has attracted the most attention in neuroscience. Because it can cross the blood-brain barrier, it delivers both an energy-boosting acetyl group and carnitine itself directly to neurons. The acetyl group can be burned for fuel, used to make the neurotransmitter acetylcholine, or incorporated into other brain chemicals including glutamate and GABA. It can also feed into lipid production for myelin, the insulating sheath around nerve fibers.16PubMed Central. L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain
In animal research, chronic ALCAR supplementation increased brain energy markers in the cortex and boosted levels of noradrenaline and serotonin, findings consistent with the idea that ALCAR could have antidepressant-like effects.17PubMed. Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice Separately, preclinical work on brain injury models has shown that ALCAR can reduce markers of oxidative stress, lower post-injury lactate levels, raise ATP, and inhibit a type of cell death driven by excessive glutamate signaling. Administration of ALCAR to rat pups after brain injury improved long-term memory outcomes.18Annals of the New York Academy of Sciences. Mechanisms of Ischemic Neuroprotection by Acetyl‐l‐carnitine The translation of these findings to human clinical practice is still ongoing, but the diversity of mechanisms, from energy rescue to antioxidant protection to neurotransmitter support, makes ALCAR one of the more intriguing acylcarnitines from a therapeutic standpoint.
Aging, Muscle Loss, and Acylcarnitine Signatures
As people age, declining mitochondrial function in skeletal muscle is thought to contribute to sarcopenia, the progressive loss of muscle mass and strength. Acylcarnitine profiling is emerging as one way to catch this process early. In a study of older Taiwanese adults, the ratio of butyrylcarnitine (C4) to creatinine stood out as a risk factor not just for early-stage muscle weakness but also for severe sarcopenia, independent of age and BMI.19PubMed Central. Plasma acylcarnitine in elderly Taiwanese: as biomarkers of possible sarcopenia and sarcopenia
A separate study in older men identified isovalerylcarnitine (C5) as associated with sarcopenia and low muscle mass, while medium-chain species like C8, C10, C12, and C14 were linked to both muscle mass and grip strength. Of these, C12, C14, and a related lipid species also tracked with walking speed.20PubMed Central. Specific lysophosphatidylcholine and acylcarnitine related to sarcopenia and its components in older men These are early findings, but they suggest that acylcarnitine profiles could eventually be part of a blood-based screening panel for age-related muscle decline, which currently relies on physical performance tests and imaging.
How Diet, Drugs, and the Gut Microbiome Shift the Profile
Your acylcarnitine profile is not fixed. It shifts in response to what you eat, what medications you take, and even what bacteria live in your gut. This matters because clinicians interpreting these profiles need to account for those influences to avoid misdiagnosis.
The ketogenic diet, used to manage drug-resistant epilepsy in children, provides a clear example. Because the diet forces the body to burn fat almost exclusively, acylcarnitine levels change predictably. In children monitored over 12 months of ketogenic diet therapy, 3-hydroxybutyrylcarnitine (C4-OH) rose significantly, reflecting increased ketone body production, while several other species including propionylcarnitine (C3) and isovalerylcarnitine (C5) decreased.21PubMed Central. An Examination of Serum Acylcarnitine and Amino Acid Profiles at Different Time Point of Ketogenic Diet Therapy and Their Association of Ketogenic Diet Effectiveness Even short-term fasting at the start of a ketogenic diet caused measurable changes, with the acetylcarnitine-to-free-carnitine ratio increasing markedly.22Pediatric Research. Monitoring of Ketogenic Diet for Carnitine Metabolites by Subcutaneous Microdialysis
Medications can have their own impact. Valproic acid, a widely prescribed anti-seizure drug, alters acylcarnitine profiles in children with epilepsy. Patients on valproate monotherapy showed elevated levels of certain species without depleting free carnitine, but those on combination drug therapy had higher long-chain acylcarnitines and a shifted ratio of long-chain species to free carnitine.23PubMed. Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS/MS Technical guidelines from the American College of Medical Genetics and Genomics explicitly note that factors like medium-chain triglyceride formulas, fasting, ketogenic diets, carnitine supplements, and intravenous nutrition can all influence results, potentially masking or mimicking disease patterns.24Genetics in Medicine. ACMG Technical Standard Laboratory analysis of acylcarnitines, 2020 update
The gut microbiome adds another layer. Research in mice has shown that specific gut bacteria influence acylcarnitine synthesis, and that estrogen status interacts with this process. When ovariectomized mice (modeling post-menopausal estrogen loss) received estrogen supplementation, their gut bacterial composition shifted in ways that promoted acylcarnitine production and improved lipid metabolism. Intriguingly, mice with depleted gut bacteria showed even greater acylcarnitine synthesis with estrogen supplementation, suggesting the microbiome normally restrains some of this production.25PubMed Central. Gut Microbiota and Acylcarnitine Metabolites Connect the Beneficial Association between Estrogen and Lipid Metabolism Disorders in Ovariectomized Mice
Measuring Acylcarnitines at Scale
The technology for measuring acylcarnitines has become remarkably sophisticated. Modern methods using liquid chromatography coupled with tandem mass spectrometry can now quantify dozens of species in a single blood sample, including odd-numbered and isomeric forms that exist at extremely low concentrations.26PubMed Central. An LC-MS/MS method to quantify acylcarnitine species including isomeric and odd-numbered forms in plasma and tissues One recent method pushed this even further, building a database capable of tracking over 1,100 acylcarnitine species in a single ten-minute run across multiple sample types.27Journal of Pharmaceutical Analysis. Simultaneously quantifying hundreds of acylcarnitines in multiple biological matrices within ten minutes using ultrahigh-performance liquid-chromatography and tandem mass spectrometry
This analytical firepower is what has made the clinical and research advances described throughout this article possible. Twenty years ago, screening could detect a handful of species. Now, the limiting factor is less about measurement and more about interpretation: understanding what each of those hundreds of species means across different tissues, diseases, ages, and dietary contexts. The field is generating data far faster than it can fully make sense of it, which is both the promise and the bottleneck of acylcarnitine science.